Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer
AstraZeneca and Daiichi Sankyo have initiated DESTINY-Endometrial02, a global phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) as an adjuvant treatment for patients with HER2-expressing endometrial cancer.
